ADMA Biologics (ADMA) reported Q4 earnings Monday of $0.46 per diluted share, compared with a loss of $0.08 a year earlier.
Three analysts polled by FactSet expected $0.15.
Revenue in the three months ended Dec. 31 rose to $117.5 million from $73.9 million a year earlier.
Three analysts surveyed by FactSet expected $112.8 million.
The company boosted its 2025 revenue forecast to $490 million from $465 million and forecast 2026 revenue of $605 million.
Three analysts polled by FactSet expect revenue of $479.2 million in 2025 and $599 million in 2026.
The company's shares rose 6.2% in after-hours trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments